DataMEDS Unit Supplies Six Peptides to Corexa
Corexa Health will supply bulk drug substances for six peptides that were recommended by an FDA advisory committee in July 2026.
Updated on Nov. 2, 2026 in Diabetes
Live Poll
Should unapproved peptide drugs be available through pharmacies with a doctor's prescription?
DataMEDS AI subsidiary Corexa Health agreed to commercially supply bulk drug substances and APIs for six peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. Corexa Pharmacy plans to dispense compounded prescriptions for the six peptides in November 2026.
Why it matters
The six peptides are compounded drugs that have not been approved by the FDA or evaluated by the agency for safety or efficacy. Corexa says the arrangement aims to give physicians a pharmacy-compounded alternative to unregulated research-use-only peptide products sold online.
The six peptides were recommended by the FDA's Pharmacy Compounding Advisory Committee at its July 23-24, 2026 meeting, and Corexa Pharmacy's network includes more than 6,500 independent pharmacies. The agreement does not disclose supply volumes, pricing or the timeline for FDA review of the peptides beyond the advisory recommendation.
The players
Corexa Health
Corexa Health is the third-party logistics and supply subsidiary of DataMEDS that manages bulk drug substance and API supply for manufacturers from a warehouse in Lakeland, Florida.
DataMEDS
DataMEDS is a company that operates the Health Lives Here mobile application and an AI-focused health technology business.
U.S. Food and Drug Administration
The FDA is the federal agency that regulates drugs in the United States and convened the advisory committee that recommended the six peptides.
The details
Corexa Pharmacy will dispense compounded versions of the six peptides under HHS's updated Enforcement Discretion Policy, with safety data collected and reported through DataMEDS's Health Lives Here mobile application. Corexa helps manufacturers manage bulk drug substance and API supply through its Lakeland, Florida, warehouse, and the agreement supports its third-party logistics business.
Timeline
July 23-24, 2026: FDA advisory committee recommended the six peptides.
Oct. 16, 2026: DataMEDS supported the FDA's proposed interim peptide access policy.
Nov. 2, 2026: DataMEDS announced the Corexa peptide supply agreement.
November 2026: Corexa Pharmacy plans to begin dispensing compounded peptide prescriptions.
Regulatory Context
The supply agreement operates under HHS's updated Enforcement Discretion Policy, which permits compounded versions of the six peptides to be dispensed while they remain outside FDA approval. The arrangement extends that policy into commercial bulk drug substance supply for BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.
Physicians may gain a pharmacy-compounded option for these six peptides in place of unregulated research-use-only products bought online. Patients considering these compounded drugs should note that they are not FDA-approved and have not been evaluated by the agency for safety or efficacy.
The takeaway
Compounded peptides supplied under an enforcement discretion policy are not FDA-approved, so readers weighing them should ask their physician about the evidence and safety data available for each product.
What happens next
Corexa Pharmacy plans to begin dispensing compounded prescriptions for the six peptides in November 2026.
Further reading
Explore more Diabetes coverage for context on peptide therapies and how they are regulated.
Source note: This article includes information reported by Benzinga.
Live Poll
Should unapproved peptide drugs be available through pharmacies with a doctor's prescription?
